Disease · HP_0000572
Visual loss
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Visual loss. Diseases, record HP_0000572. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000572
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Visual loss
- Open Targets ID
- HP_0000572
- Other names
- Loss of vision, Vision loss
- Highest stage of its drugs
- Phase 3, for 6 of its 16 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs16
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| RANIBIZUMAB | CHEMBL1201825 | Antibody | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| AFLIBERCEPT | CHEMBL1742982 | Protein | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ALTEPLASE | CHEMBL1201593 | Enzyme | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| TRIAMCINOLONE ACETONIDE | CHEMBL1504 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ASPIRIN | CHEMBL25 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| IDEBENONE | CHEMBL252556 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ACETAZOLAMIDE | CHEMBL20 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACETYLCYSTEINE | CHEMBL600 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| DEXAMETHASONE | CHEMBL384467 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LARUPARETIGENE ZOVAPARVOVEC | CHEMBL5095428 | Gene | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 16
See all 16 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| VEGFA | Vascular endothelial growth factor A, long form | 3 | Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor | Phase 3 | https://conductscience.org/library/genes/7422 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 2 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| CA1 | Carbonic anhydrase 1 | 1 | Carbonic anhydrase I inhibitor | Phase 2/3 | https://conductscience.org/library/genes/759 | Drugs and targets |
| CA12 | Carbonic anhydrase 12 | 1 | Carbonic anhydrase XII inhibitor | Phase 2/3 | https://conductscience.org/library/genes/771 | Drugs and targets |
| CA2 | Carbonic anhydrase 2 | 1 | Carbonic anhydrase II inhibitor | Phase 2/3 | https://conductscience.org/library/genes/760 | Drugs and targets |
| CA4 | Carbonic anhydrase 4 | 1 | Carbonic anhydrase IV inhibitor | Phase 2/3 | https://conductscience.org/library/genes/762 | Drugs and targets |
| IL2RA | Interleukin-2 receptor | 1 | Interleukin-2 receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/3559 | Drugs and targets |
| IL2RB | Interleukin-2 receptor | 1 | Interleukin-2 receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/3560 | Drugs and targets |
| IL2RG | Interleukin-2 receptor | 1 | Interleukin-2 receptor inhibitor | Phase 1 | https://conductscience.org/library/genes/3561 | Drugs and targets |
| PGF | Placenta growth factor | 1 | Placenta growth factor inhibitor | Phase 3 | https://conductscience.org/library/genes/5228 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01909791 | Treatment for CI-DME in Eyes With Very Good VA Study | Phase 3 | 702 | 2020-01-03 | Diabetic Macular Edema | AFLIBERCEPT | Its record names the disease | ClinicalTrials.gov |
| NCT00444600 | Laser-Ranibizumab-Triamcinolone for Diabetic Macular Edema | Phase 3 | 691 | 2011-07-12 | Diabetic Retinopathy, Diabetic Macular Edema | RANIBIZUMAB, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00445003 | Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy | Phase 3 | 333 | 2011-07-13 | Proliferative Diabetic Retinopathy, Diabetic Macular Edema | RANIBIZUMAB, TRIAMCINOLONE ACETONIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01003639 | Idiopathic Intracranial Hypertension Treatment Trial | Phase 2/3 | 165 | 2018-12-12 | Idiopathic Intracranial Hypertension | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01648452 | CNTF Implants for CNGB3 Achromatopsia | Phase 1/2 | 5 | 2014-02-25 | Eye Disease, Achromatopsia | CILIARY NEUROTROPHIC FACTOR | Its record names the disease | ClinicalTrials.gov |
| NCT00561834 | Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy | Phase 1 | 2 | 2016-07-25 | Nonarteritic Anterior Ischemic Optic Neuropathy | RANIBIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04663750 | Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER). | Phase 3 | 210 | Eye Diseases, Macular Degeneration, Wet, Sub-Macular Hemorrhage | AFLIBERCEPT, ALTEPLASE | Its record names the disease | ClinicalTrials.gov | |
| NCT06919744 | Intracranial Venous Stenting Evaluation in Patients With Idiopathic Intracranial Hypertension in the Early Phase | Not applicable | 114 | Idiopathic Intracranial Hypertension (IIH) | ACETAZOLAMIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT03197194 | A Phase III Randomized, Blind, Double Dummy, Multicenter Study Assessing the Efficacy and Safety of IV THrombolysis (Alteplase) in Patients With acutE Central retInal Artery Occlusion | Phase 3 | 70 | Central Retinal Artery Occlusion | ALTEPLASE, ASPIRIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00121589 | Lutein/Zeaxanthin and Omega-3 Supplementation in Persons Over Age 60 | Phase 1 | 40 | Macular Degeneration | DOCONEXENT, LUTEIN, ZEAXANTHIN | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Acetazolamide vs Sugar Pill: serious adverse events | 9 of 86 | 7 of 79 | 165 | NCT01003639 | Trial comparisons |
| NT-501 CNTF-releasing Implant Events ≤ 6 Months Post-implant vs NT-501 CNTF-releasing Implant Events > 6 Months Post-implant: serious adverse events | 1 of 5 | 1 of 5 | 10 | NCT01648452 | Trial comparisons |
Papers from its trials27
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000572
GET https://conductscience.org/api/diseases/v1/HP_0000572/papers?page=2